Skip to content

Attention Training for Learning Enhancement and Resilience Trial

Attention Training for Learning Enhancement and Resilience Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02416401
Acronym
ALERT
Enrollment
83
Registered
2015-04-15
Start date
2015-11-30
Completion date
2017-12-31
Last updated
2018-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age-related Cognitive Decline

Keywords

healthy, aging, cognition, age-related cognitive decline

Brief summary

Healthy aging is associated with a decline in multiple cognitive domains, as well as motor control function. The long-term consequences of cognitive and functional impairment resulting from age-related cognitive decline are well documented in the scientific and clinical literature, with significant evidence of related problems with independent functional abilities. This study aims to understand how the experimental computer program can affect cognition and attention in participants with age-related cognitive decline.

Detailed description

Following consent, participants will engage in an assessment process to determine eligibility. Once eligibility is confirmed, participants will be scheduled for another assessment session to determine current level of cognitive function. This process consists of paper-pencil surveys and computerized tests. Following the assessment process, participants will engage in an Internet browser-delivered training sessions conducted on any internet-accessible computer. The computerized training sessions can be done up to 7 times a week (once a day) or at the participant's convenience (the recommended time commitment is 5 times a week). Following the completion of training, the participant's cognitive function will be re-assessed. Participation is voluntary and participants may withdraw from the study at any time.

Interventions

Sponsors

University of Iowa
CollaboratorOTHER
Harvard Medical School (HMS and HSDM)
CollaboratorOTHER
Posit Science Corporation
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Participants must be 65 years of age or older * Participants must have a diagnosis of age-related cognitive decline as confirmed by interview and performance on screening assessments * Participants must be fluent English speakers * Participants must have adequate visual, auditory, and motor capacity to use computerized intervention

Exclusion criteria

* Participants with diagnosis of PTSD, depression or other psychologically diagnosable emotional disorder * Participants with a history of conditions that could affect thinking abilities, including brain injury, mental illness, cancer, or other neurological conditions (multiple sclerosis, seizure disorder), HIV/AIDS will be excluded * Participants enrolled in another concurrent research study will be excluded * Participants who have difficulty performing assessments or comprehending or following spoken instructions, in the judgment of the screening clinician, will be excluded * Participants with a current or significant past history of substance abuse will be excluded * Participants who show signs of suicidal ideations or behaviors will be excluded and referred for appropriate treatment

Design outcomes

Primary

MeasureTime frameDescription
Attention Measures aimed to test attention6 monthsMeasures aimed to test attention
Executive Function6 monthsTasks targeting inhibitory control
Functional Capacity6 monthPerformance on directly observable functional measure

Secondary

MeasureTime frameDescription
Quality of Sleep6 monthsassessing sleep quality

Other

MeasureTime frameDescription
Quality of life6 monthsAssessments and questionnaire assessing quality of life

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026